Neurotechnology · Strategy · Capital · Access

Good science is not a business strategy.

Platt & Associates helps neurotechnology companies, investors, and institutions turn complex science into commercial decisions—and the right relationships into forward motion.

The hard part

Neurotechnology rarely fails for lack of intelligence.

It fails when teams confuse technical progress with market readiness, mistake interest for demand, or begin fundraising before their story can survive serious scrutiny.

We find those gaps early. Then we build the commercial logic, stakeholder strategy, and relationships required to close them.

Built inside the field

A strategist, editor, educator—and active member of the neurotech community.

Program

Founding Co-Chair, Cleveland NeuroDesign

JoJo co-founded the Cleveland NeuroDesign Entrepreneurs Workshop in 2019 to prepare the next generation of neurotechnology founders and leaders. The intensive program applies the Stanford Biodesign process to the commercial realities of BCIs, neuromodulation, digital health, and related medical technologies.

Editorial

Senior Contributing Editor, Neurotech Reports

Her editorial work keeps her close to the companies, technologies, investors, and market shifts shaping neurotechnology. She brings that current, cross-sector perspective into every client engagement—not a snapshot assembled after the fact.

Community

A trusted voice in the neurotech community

JoJo has built a strong LinkedIn following through candid, useful content created specifically for the neurotechnology community. Her audience includes founders, investors, researchers, operators, and industry leaders who value clear analysis over promotional noise.

What we do

Strategy for the decisions that actually change the outcome.

01

Commercialization strategy

Turn promising science into a defensible business case. Market sizing, indication selection, competitive intelligence, reimbursement logic, and go-to-market strategy—built for the realities of neurotechnology.

02

Capital strategy and investor readiness

Sharpen the story before it reaches the room. Positioning, pitch critique, fundraising strategy, investor targeting, and candid preparation from someone who understands both sides of the table.

03

Strategic access and partnerships

Identify the people who can change the trajectory—investors, operators, clinicians, researchers, manufacturers, and channel partners—and build a credible path to engagement.

04

U.S. market entry

Pressure-test the assumptions international teams make about the United States. Clarify the market, stakeholder map, regulatory and reimbursement questions, and sequence of entry before capital is wasted.

05

Ecosystems and convenings

Design high-value programs, workshops, panels, and investor engagements that create durable relationships—not another event where everyone leaves with a stack of business cards and no next move.

Where we operate

At the intersection of the laboratory, the boardroom, and the market.

Brain–computer interfaces Neuromodulation Bioelectronic medicine Neural data Brain health Neurodiagnostics Wearable and implantable neurotechnology

JoJo Platt · Founder

Pattern recognition built across the neurotechnology ecosystem.

JoJo Platt is a neurotechnology strategist, startup advisor, investor representative, and Senior Contributing Editor at Neurotech Reports.

Her work spans early-stage commercialization, venture diligence, investor engagement, strategic partnerships, international market entry, and the design of programs that connect emerging leaders with the people and resources that move companies forward.

As a founding co-chair of the Cleveland NeuroDesign Entrepreneurs Workshop, she has helped build an internationally recognized, highly selective program that has trained nearly 200 emerging neurotechnology leaders since 2019. Its alumni have gone on to become founders, funders, and industry leaders.

Her editorial work and ongoing LinkedIn engagement provide a continuous view of the neurotech ecosystem: what companies are building, what investors are questioning, which narratives are gaining traction, and where the market is moving next.

The value is not another framework. It is knowing which question matters next—and being willing to answer it honestly.

A useful first conversation

You should call us when…

  • Your technology is advancing faster than your commercial thesis.
  • Your pitch gets polite interest but no committed capital.
  • You need to choose a market—not justify the one you already chose.
  • You are entering the U.S. and need reality, not reassurance.
  • You need access to an ecosystem, but first need a credible reason to engage it.

Frequently asked questions

Neurotechnology commercialization, answered directly.

What does a neurotechnology commercialization consultant do?
A neurotechnology commercialization consultant helps translate scientific and technical progress into a viable business strategy. The work can include market selection, competitive intelligence, indication prioritization, reimbursement logic, go-to-market planning, investor positioning, and strategic partnerships.
Who does Platt & Associates work with?
Platt & Associates works with neurotechnology startups, growth-stage companies, investors, research institutions, academic spinouts, and international teams preparing to enter the United States.
Which neurotechnology sectors does Platt & Associates cover?
Core areas include brain-computer interfaces, neuromodulation, bioelectronic medicine, neural data, brain health, neurodiagnostics, and wearable and implantable neurotechnology.
Can Platt & Associates help a neurotech company prepare to raise capital?
Yes. Support includes commercial positioning, pitch critique, fundraising strategy, investor targeting, market evidence, and preparation for difficult investor questions. The objective is not cosmetic storytelling; it is a financing case that withstands scrutiny.
Does Platt & Associates support U.S. market entry?
Yes. Platt & Associates helps international neurotechnology companies evaluate U.S. market assumptions, map stakeholders, identify regulatory and reimbursement questions, prioritize partners, and sequence market entry before committing significant capital.

Start with the real problem

What decision can’t you afford to get wrong?

Send a concise description of the technology, the decision in front of you, and what happens if you get it wrong. If we can help, we will tell you how. If we cannot, we will tell you that too.

Start a conversation